牛牛AI助理已提取核心訊息
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the fourth quarter and full year of 2023 on February 1, 2024. The company announced a 6% increase in fourth-quarter worldwide sales to $14.6 billion compared to the same period in 2022, with full-year sales rising 1% to $60.1 billion. The growth was attributed to strong performance in oncology and vaccines, particularly KEYTRUDA and GARDASIL/GARDASIL 9. However, the company experienced a GAAP loss per share of $0.48 for the quarter, including a charge of $1.69 per share for a collaboration with Daiichi Sankyo. Non-GAAP EPS was $0.03. Full-year GAAP EPS was $0.14, and non-GAAP EPS was $1.51, both including significant charges related to business development transactions. Merck also announced the approval of a new restructuring program aimed at optimizing its manufacturing network, with expected completion by the end of 2031 and estimated costs of approximately $4.0 billion. The company's financial outlook for 2024 anticipates worldwide sales between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the fourth quarter and full year of 2023 on February 1, 2024. The company announced a 6% increase in fourth-quarter worldwide sales to $14.6 billion compared to the same period in 2022, with full-year sales rising 1% to $60.1 billion. The growth was attributed to strong performance in oncology and vaccines, particularly KEYTRUDA and GARDASIL/GARDASIL 9. However, the company experienced a GAAP loss per share of $0.48 for the quarter, including a charge of $1.69 per share for a collaboration with Daiichi Sankyo. Non-GAAP EPS was $0.03. Full-year GAAP EPS was $0.14, and non-GAAP EPS was $1.51, both including significant charges related to business development transactions. Merck also announced the approval of a new restructuring program aimed at optimizing its manufacturing network, with expected completion by the end of 2031 and estimated costs of approximately $4.0 billion. The company's financial outlook for 2024 anticipates worldwide sales between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
領先的製藥公司默沙東公司於2024年2月1日公佈了其2023年第四季度和全年財務業績。該公司宣佈，與2022年同期相比，第四季度全球銷售額增長6％，達到146億美元，全年銷售額增長1％，達到601億美元。增長歸因於腫瘤學和疫苗領域的強勁表現，尤其是KEYTRUDA和GARDASIL/GARDASIL 9。但是，該公司本季度的GAAP每股虧損爲0.48美元，其中包括與第一三共合作的每股1.69美元的費用。非公認會計准則每股收益爲0.03美元。全年公認會計准則每股收益爲0.14美元，非公認會計准則每股收益爲1.51美元，均包括與業務發展交易相關的重大費用。默沙東還宣佈批准一項旨在優化其製造網絡的新重組計劃，預計將於2031年底完成，預計成本約爲40億美元。該公司2024年的財務展望預計全球銷售額在627億美元至642億美元之間，非公認會計准則每股收益預計在8.44美元至8.59美元之間。
領先的製藥公司默沙東公司於2024年2月1日公佈了其2023年第四季度和全年財務業績。該公司宣佈，與2022年同期相比，第四季度全球銷售額增長6％，達到146億美元，全年銷售額增長1％，達到601億美元。增長歸因於腫瘤學和疫苗領域的強勁表現，尤其是KEYTRUDA和GARDASIL/GARDASIL 9。但是，該公司本季度的GAAP每股虧損爲0.48美元，其中包括與第一三共合作的每股1.69美元的費用。非公認會計准則每股收益爲0.03美元。全年公認會計准則每股收益爲0.14美元，非公認會計准則每股收益爲1.51美元，均包括與業務發展交易相關的重大費用。默沙東還宣佈批准一項旨在優化其製造網絡的新重組計劃，預計將於2031年底完成，預計成本約爲40億美元。該公司2024年的財務展望預計全球銷售額在627億美元至642億美元之間，非公認會計准則每股收益預計在8.44美元至8.59美元之間。
有用
沒用